Applied BioCode Announces Retirement of CEO Chris Bernard

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)-- Applied BioCode announced today the retirement of Chris Bernard as Chief Executive Officer. Chris Bernard has served as CEO for the past two years and has been instrumental in guiding the company through a period of growth and innovation. During his tenure, Chris played a pivotal role in advancing Applied BioCode’s strategic initiatives and driving the company’s commitment to delivering cutting-edge solutions to the molecular diagnostics market. His leadership and dedication have been invaluable in positioning Applied BioCode as a leader in multiplex testing technologies.

Following his retirement, Winston Ho, Ph.D., Founder and President, will step into the role of Chief Executive Officer until a new CEO is appointed. “I am honored to once again have the opportunity to lead Applied BioCode as we continue our mission to revolutionize multiplex testing and improve healthcare outcomes,” said Dr. Winston Ho. “I want to extend my heartfelt thanks to Chris for his leadership and dedication to the company. I am committed to building upon the strong foundation we have laid.”

Applied BioCode remains steadfast in its commitment to delivering innovative solutions that empower researchers, clinicians, and healthcare providers to make more informed decisions and enhance patient care.

To learn more about the Applied BioCode team and offerings visit: https://www.apbiocode.com/products/

About Applied BioCode:

Applied BioCode is an IVD manufacturer that designs, develops, and commercializes multiplex testing products. The company has combined “digital barcodes” with immuno- and molecular chemistry to create a new, bio-inspired Barcoded Magnetic Beads (BMB) technology. The micro BMBs, about the diameter of a human hair, are tagged with immunochemistry or molecular probes, allowing the digital barcodes to be easily scanned and accurately identified up to 4,096 barcodes with no ambiguity for biological targets. The company has FDA 510K clearances for their 17-plex Respiratory Pathogen Panel (RPP) and 17-plex Gastrointestinal Pathogen Panel (GPP) based on their BioCode® MDx-3000 automated system. The GPP and RPP are CE-Marked for use in European countries conforming to CE-Mark regulations. Applied BioCode, Inc. has also been granted an Emergency Use Authorization (EUA) from the U.S. FDA for its BioCode® SARS-CoV-2 Flu Plus Assay ⱡ, BioCode® SARS-CoV-2 Assay*, and an additional EUA for Pooled COVID-19 Testing*. Applied BioCode also partners with a variety of diagnostic companies with applications that include infectious disease, autoimmune disease, allergy, gut microbiome, and veterinary markets.

ⱡ This product has not been FDA cleared or approved but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection and differentiation of nucleic acid from SARS-CoV-2, Influenza A (with H1 pdm09, H1 seasonal, H3 subtypes), Influenza B, and/or Respiratory Syncytial Virus (RSV), not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

* This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21. U.S.C. § 360bbb3(b)(1), unless the authorization is terminated or revoked sooner.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240325257894/en/